Pressure on drug pricing, shifting political forces in key markets and potential tax relief in the US support a positive outlook for 2017 life sciences M&A.
The 2017 outlook for life sciences
It’s time to bring drug pricing down
The drug pricing debate: Managing risks to results
Do India’s growth opportunities outweigh the market challenges?
SEC comments and trends: Life sciences
Technical line - Definition of a business: update for life sciences entities
EY M&A Outlook and Firepower Report 2017
Reshaping biopharmaceutical business models
Life sciences customer experience: what’s next?
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Network brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.
But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.
We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.
We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.
So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.
Take a closer look:
Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.
We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.
Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.
Take a closer look:
- Medical technology
Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.
Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.
Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.
From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.
Take a closer look:
Connect with us
Life Science Alert
How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.